How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

Ines Suarez-García1,2, Belén Alejos3, Maria-Jesús Pérez-Elías4, Jose-Antonio Iribarren5, Asunción Hernando2,6, Margarita Ramírez7, María Tasias8, Mario Pascual9, Inma Jarrin3†, Victoria Hernando3*† and CoRIS Cohort

Abstract

Background: To estimate the prevalence and severity of menopausal symptoms and anxiety/depression and to assess the differences according to menopausal status among women living with HIV aged 45–60 years from the cohort of Spanish HIV/AIDS Research Network (CoRIS).

Methods: Women were interviewed by phone between September 2017 and December 2018 to determine whether they had experienced menopausal symptoms and anxiety/depression. The Menopause Rating Scale was used to evaluate the prevalence and severity of symptoms related to menopause in three subscales: somatic, psychological and urogenital; and the 4-item Patient Health Questionnaire was used for anxiety/depression. Logistic regression models were used to estimate odds ratios (ORs) of association between menopausal status, and other potential risk factors, the presence and severity of somatic, psychological and urogenital symptoms and of anxiety/depression.

Results: Of 251 women included, 137 (54.6%) were post-, 70 (27.9%) peri- and 44 (17.5%) pre-menopausal, respectively. Median age of onset menopause was 48 years (IQR 45–50). The proportions of pre-, peri- and post-menopausal women who had experienced any menopausal symptoms were 45.5%, 60.0% and 66.4%, respectively. Both peri- and post-menopause were associated with a higher likelihood of having somatic symptoms (aOR 3.01; 95% CI 1.38–6.55 and 2.63; 1.44–4.81, respectively), while post-menopause increased the likelihood of having psychological (2.16; 1.13–4.14) and urogenital symptoms (2.54; 1.42–4.85). By other hand, post-menopausal women had a statistically significant five-fold increase in the likelihood of presenting severe urogenital symptoms than pre-menopausal women (4.90; 1.74–13.84). No significant differences by menopausal status were found for anxiety/depression. Joint/muscle problems, exhaustion and sleeping disorders were the most commonly reported symptoms among all women. Differences in the prevalences of vaginal dryness (p = 0.002), joint/muscle complaints (p = 0.032), and sweating/flush (p = 0.032) were found among the three groups.

Conclusions: Women living with HIV experienced a wide variety of menopausal symptoms, some of them initiated before women had any menstrual irregularity. We found a higher likelihood of somatic symptoms in peri- and
Introduction
Life expectancy among people living with HIV has increased since the advent of highly active antiretroviral therapy (HAART) [1] and thus, many women living with HIV will live to experience menopause. In Spain, 15% of all new HIV diagnoses [2], and 29% of all people living with HIV are women [3]. Median age of women living with HIV has increased from 38.0 years in the year 2003 to 48.6 years in 2018 [3]. These data show that an increasing number of women living with HIV will face the transition to menopause.

Hormonal changes that occur during this stage of women's life can cause symptoms that impair their quality of life [4]. The symptoms related to menopause include hot flushes, vaginal dryness, sleep disturbances, and psychological and cognitive changes, but not all women will develop these symptoms during the transition to menopause, and not all will develop them with the same intensity [5]. Biological, psychosocial and cultural factors may influence the development of menopausal symptoms, and each woman can experience menopause differently [6]. Although these symptoms are usually of mild intensity and self-limiting, disappearing as the woman progresses in the transition to menopause, they can nevertheless interfere with her daily activities and quality of life.

Women living with HIV infection already face a worse quality of life than men living with HIV [7, 8], and menopausal symptoms can impair their physical wellbeing, although existing studies show conflicting data [9–13]. Moreover, most of the published studies have been performed in North America, where the clinical and psychosocial characteristics of women with HIV may differ from those in other European countries [14].

The aim of our study was to investigate the prevalence and severity of menopausal symptoms, and of anxiety and depression in women living with HIV aged 45–60 years at 30 November 2016. CoRIS is a prospective, open, multicenter cohort of individuals newly diagnosed with HIV, naïve to antiretroviral treatment at cohort entry. By November 2016, 31 centers from 13 Autonomous Regions in the Spanish public healthcare system were participating in CoRIS. The cohort has been described in detail elsewhere [15].

Methods

Study population
We included all cis-women from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) aged between 45 and 60 years at 30 November 2016. CoRIS is a prospective, open, multicenter cohort of individuals newly diagnosed with HIV, naïve to antiretroviral treatment at cohort entry. By November 2016, 31 centers from 13 Autonomous Regions in the Spanish public healthcare system were participating in CoRIS. The cohort has been described in detail elsewhere [15].

Questionnaire design and administration
We used a questionnaire similar to that proposed by Tariq et al. for the PRIME Study [16] to collect sociodemographic, women's health, sexual, medical and HIV-related information.

The Menopause Rating Scale (MRS) was used to assess the presence and severity of menopausal symptoms [17], which has been used among several populations, including women living with HIV [10, 18]. The MRS is a self-reported subjective scale consisting of 11 items arranged in three subscales: somatic symptoms (sweating/flushes, cardiac complaints, sleeping disorders, and joint/muscle complaints); psychological symptoms (feeling depressed, irritable, anxious, and exhausted); and urogenital symptoms (sexual problems, urinary complaints, and vaginal dryness). Each item is graded as 0 (not present), 1 (mild), 2 (moderate), 3 (severe) or 4 (very severe). The MRS total score is the sum of the scores obtained for each subscale. Somatic, psychological and urogenital symptoms were considered to be present if the sum scores for each specific sub-scale was equal to or above 3, 2 and 1, respectively. Symptoms were considered severe if the score was equal to or above 9 in the somatic sub-scale, 7 in the psychological sub-scale and 4 in the urogenital sub-scale. For each sub-scale, each specific symptom was considered to be present if it scored equal to or above 2.

The 4-item Patient Health Questionnaire (PHQ-4) was used to specifically evaluate the current presence of symptoms of anxiety and depression [19, 20]. Women were asked how often they had been bothered over the last two weeks by the following problems: feeling nervous, anxious or on edge; not being able to stop or control worrying; feeling down, depressed or hopeless; and having little interest or pleasure in doing things. Each question was graded as 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day). The total score was determined by adding together the scores for each of the 4 items. A total score higher than 3 for the...
questions “Feeling nervous, anxious or on edge” and “Not being able to stop or control worrying” was identified as anxiety. A total score higher than 3 for the questions “Feeling down, depressed or hopeless” and “Little interest or pleasure in doing things” was identified as depression. Both anxiety and depression were considered to be present if the total score was equal to or above 6.

Social support was evaluated through a 4-item MOS-SSS version [21], ranging from 1 (never) to 5 (all of the time) for each item. “Social support” was classified as “poor” when the score was below 12 points and “normal” if the score was 12 points or higher.

A healthcare provider in each participant center contacted the women who met inclusion criteria to explain the project and to request their participation and written consent. Women who agreed to participate were interviewed by phone between September 2017 and December 2018. Responses were anonymized for the investigators analyzing the data.

**Menopausal status definitions**

Menopausal status was self-reported, as, in other similar published studies [9, 11, 22, 23], and was categorized as: pre-menopausal, if a woman had regular menstruation; peri-menopausal, if a woman reported amenorrhea for at least three months in the previous year; and post-menopausal, if a woman had 12 consecutive months of amenorrhea. Women who had a history of hysterectomy and/or bilateral oophorectomy were excluded.

**Statistical analysis**

Sociodemographic and clinical characteristics according to menopausal status were summarized using frequency distributions for categorical variables and median and interquartile range (IQR) for continuous ones. The $\chi^2$ test for independence was used for comparison of categorical variables and the non-parametric Kruskal–Wallis test for comparison of continuous ones.

We described the prevalence and the severity of somatic, psychological and urogenital symptoms, the prevalence of each specific symptom and the prevalence of anxiety and depression, according to menopausal status.

Logistic regression models were used to estimate odds ratios (ORs) of association between menopausal status, and other potential risk factors, the presence and severity of somatic, psychological and urogenital symptoms, and of anxiety and depression. Multivariable models included menopausal status, mode of transmission (heterosexual, injecting drug users (IDU), other), current occupational status (employed, unemployed, others), current partner (no, yes) smoking (never/past, current), drug use (never/sporadic, past/current) and social support (normal, poor). Wald tests were used to derive p values. All statistical analyses were performed using Stata software (version 16.0; Stata Corporation, College Station, TX, USA).

**Ethics**

Each patient signed an informed consent to participate in the cohort. The HIV Biobank Ethics’ Committees approved the CoRIS cohort and the Ethics Committee of the Carlos III Institute of Health approved this study.

**Results**

The CoRIS database, updated on November 30th, 2016, included data from 10,316 individuals, of which 1,681 were women; of these, 528 women were aged between 45 and 60 years. Among the 528 women aged 45–60 years, 277 were excluded for the following reasons: 97 (35.0%) declined to participate in the study, 93 (33.6%) could not be contacted, 36 (13.0%) had a history of hysterectomy and/or bilateral oophorectomy; 20 (7.2%) had died between their last registered visit in the cohort and this study, and 31 (11.2%) were excluded for different reasons (not speaking Spanish, health problems, being transgender, not having a phone). The women who were excluded were more likely to have low educational level ($p<0.001$) and to have been born in countries other than Spain or South American countries ($p<0.001$) compared to those who were included in the study.

Finally 251 women were included in this study, of which 137 (54.6%) had reached menopause, 70 (27.9%) were peri-menopausal and 44 (17.5%) were pre-menopausal. Among menopausal women, the median age at their final menstrual period was 48 years (IQR 45–50).

The sociodemographic and clinical characteristics according to menopausal status are shown in Table 1.

The median age was 46, 49 and 55 years for pre-, peri- and post-menopausal women, respectively ($p<0.001$). Pre-menopausal women were more likely to have been born in countries other than Spain (40.9%) compared with peri- and post-menopausal women (24.3% and 21.2%, respectively). Post-menopausal women most frequently had a partner with whom they lived (51.8%) whereas pre- and peri-menopausal most frequently had a partner but they did not live together (54.5% and 50.0%, respectively). Not having a partner was reported by 9.1%, 22.9% and 12.4% of pre-, peri- and post-menopausal women, respectively ($p = 0.004$). Post-menopausal women reported not having had any sexual intercourse during the last past year and having poor social support more frequently than pre-and peri-menopausal women (48.9% versus 25.0% and 22.0% [$p < 0.001$], and 22.6% versus 18.2% and 5.7% [$p = 0.002$], respectively). There were no differences between pre-, peri- and post-menopausal women regarding the consumption
| Sociodemographic and clinical characteristics of 251 women included, according to menopausal status |
|-----------------------------------------------------------------------------------------------|
|                                                                                               |
| **Menopausal status**                                                                         |
| All women                                      Pre-menopausal     Peri-menopausal    Post-menopausal       p         |
| 251 (100%)                                     44 (17.5%)          70 (27.9%)          137 (54.6%)          |<0.001               |
| **Sociodemographic variables**                  |                      |                      |                      |           |
| Age (years; median –[IQR])                     | 52 (48–55)           | 46 (45–48)           | 49 (47–52)           | 55 (52–57) |           |
| Country of origin                              | 187 (74.5%)          | 26 (59.1%)           | 53 (75.7%)           | 108 (78.8%)| 0.032     |
|     Spain                                      | 184 (73.5%)          | 24 (54.5%)           | 46 (65.7%)           | 94 (68.8%) |           |
|     Others                                     | 64 (25.5%)           | 18 (40.9%)           | 17 (24.3%)           | 29 (21.2%) |           |
| Educational level                              | 21 (8.4%)            | 2 (4.5%)             | 7 (10.0%)            | 12 (8.8%)  | 0.574     |
|     None or primary                            | 230 (91.6%)          | 42 (95.5%)           | 63 (90.0%)           | 125 (91.2%)|           |
| Current occupational status                    | 137 (54.6%)          | 24 (54.5%)           | 41 (58.6%)           | 72 (52.6%) | 0.525     |
|     Employed                                   | 45 (17.9%)           | 11 (25.0%)           | 11 (15.7%)           | 23 (16.8%) |           |
|     Unemployed                                 | 69 (27.5%)           | 9 (20.5%)            | 18 (25.7%)           | 42 (30.7%) |           |
| Current partner and cohabitation status        | 106 (42.2%)          | 16 (36.4%)           | 19 (27.1%)           | 71 (51.8%) | 0.004     |
|     Without partner                            | 108 (43.0%)          | 24 (54.5%)           | 35 (50.0%)           | 49 (35.8%) |           |
|     With partner and living together           | 37 (14.7%)           | 4 (9.1%)             | 16 (22.9%)           | 17 (12.4%) |           |
| Clinical variables                             | 23.7 (21.2–28.0)     | 24.0 (22.0–26.7)     | 23.8 (21.2–27.7)     | 23.6 (21.0–28.7)| 0.982     |
| Body mass index (kg/m²)                        | 15 (6.0%)            | 3 (6.8%)             | 2 (2.9%)             | 10 (7.3%)  | 0.482     |
|     < 18.5                                     | 136 (54.2%)          | 23 (52.3%)           | 39 (55.7%)           | 74 (54.0%) |           |
|     18.5–24.9                                  | 54 (21.5%)           | 10 (22.7%)           | 20 (28.6%)           | 24 (17.5%) |           |
|     > 30                                       | 39 (15.5%)           | 6 (13.6%)            | 7 (10.0%)            | 26 (19.0%) |           |
| Body mass index (kg/m²)                        | 7 (2.8%)             | 2 (4.5%)             | 2 (2.9%)             | 3 (2.2%)   |           |
| Hepatitis B                                    | 23.7 (21.2–28.0)     | 24.0 (22.0–26.7)     | 23.8 (21.2–27.7)     | 23.6 (21.0–28.7)| 0.982     |
|     Yes                                        | 60 (23.9%)           | 6 (13.6%)            | 18 (25.7%)           | 36 (26.3%) | 0.335     |
|     No                                         | 174 (69.3%)          | 33 (75.0%)           | 47 (67.1%)           | 94 (68.6%) |           |
|     Unknown                                    | 17 (6.8%)            | 5 (11.4%)            | 5 (7.1%)             | 7 (5.1%)   |           |
| Hepatitis C                                    | 23.7 (21.2–28.0)     | 24.0 (22.0–26.7)     | 23.8 (21.2–27.7)     | 23.6 (21.0–28.7)| 0.982     |
|     Yes                                        | 60 (23.9%)           | 6 (13.6%)            | 16 (22.9%)           | 38 (27.7%) | 0.204     |
|     No                                         | 179 (71.3%)          | 34 (77.3%)           | 50 (71.4%)           | 95 (69.3%) |           |
|     Unknown                                    | 12 (4.8%)            | 4 (9.1%)             | 4 (5.7%)             | 4 (2.9%)   |           |
| Diabetes mellitus                              | 18 (7.2%)            | 2 (4.5%)             | 4 (5.7%)             | 12 (8.8%)  | 0.549     |
|     Yes                                        | 233 (92.8%)          | 42 (95.5%)           | 66 (94.3%)           | 125 (91.2%)|           |
|     No                                         | 37 (14.7%)           | 0 (0.0%)             | 7 (10.0%)            | 30 (21.0%) | <0.001    |
|     Unknown                                    | 214 (85.3%)          | 44 (100.0%)          | 63 (90.0%)           | 107 (78.1%)|           |
| Smoking                                        | 115 (45.8%)          | 15 (34.1%)           | 35 (50.0%)           | 65 (47.4%) | 0.215     |
|     Current                                   | 136 (54.2%)          | 29 (65.9%)           | 35 (50.0%)           | 72 (52.6%) |           |
|     Never/past                                 | 202 (80.5%)          | 36 (81.8%)           | 56 (80.0%)           | 110 (80.3%)| 0.969     |
| Alcohol consumption                            | 49 (19.5%)           | 8 (18.2%)            | 14 (20.0%)           | 27 (19.7%) |           |
|     Never                                      | 154 (61.4%)          | 27 (61.4%)           | 43 (61.4%)           | 84 (61.3%) | 0.522     |
|     Sporadic use                                | 8 (3.2%)             | 3 (6.8%)             | 3 (4.3%)             | 2 (1.5%)   |           |
|
Table 1 (continued)

| Menopausal status | All women | Pre-menopausal | Peri-menopausal | Post-menopausal | p  |
|-------------------|-----------|----------------|----------------|----------------|----|
|                   | 251 (100%)| 44 (17.5%)     | 70 (27.9%)     | 137 (54.6%)    |    |
| Regular past use  |           |                |                |                |    |
| 75 (29.9%)        | 13 (29.5%)| 21 (30.0%)     | 41 (29.9%)     |                |    |
| Regular current use|          |                |                |                |    |
| 14 (5.6%)         | 1 (2.3%)  | 3 (4.3%)       | 10 (7.3%)      |                |    |
| Trouble failing asleep the last two weeks |                  |                |                |                |    |
| Never             | 137 (54.6%)| 28 (63.6%)     | 44 (62.9%)     | 65 (47.4%)     | 0.165|
| Less than twice a week |         | 5 (11.4%)      | 6 (8.6%)       | 18 (13.1%)     |    |
| More than 3 times a week |          | 11 (25.0%)     | 20 (28.6%)     | 54 (39.4%)     |    |
| Social support (MOS-SSS-4item) |                  |                |                |                |    |
| Poor (score < 12) |           |                |                |                | 0.009|
| 43 (17.1%)        | 8 (18.2%) | 4 (5.7%)       | 31 (22.6%)     |                |    |
| Normal (score ≥ 12)|        |                |                |                |    |
| 208 (82.9%)       | 36 (81.8%)| 66 (94.3%)     | 106 (77.4%)    |                |    |
| Sexual intercourse during last year |                  |                |                |                | <0.001|
| Yes               | 159 (63.3%)| 33 (75.0%)     | 56 (80.0%)     | 70 (51.1%)     |    |
| No                | 92 (36.7%)| 11 (25.0%)     | 14 (20.0%)     | 67 (48.9%)     |    |
| Age at diagnosis (years; median[IQR]) |           |                |                |                | <0.001|
| Injecting drug user |          |                |                |                |    |
| 30 (12.0%)        | 3 (6.8%)  | 10 (14.3%)     | 17 (12.4%)     |                | 0.293|
| Heterosexual      | 210 (83.7%)| 37 (84.1%)     | 59 (84.3%)     | 114 (83.2%)    |    |
| Others/Unknown    | 11 (4.4%) | 4 (9.1%)       | 1 (1.4%)       | 6 (4.4%)       |    |
| Time since HIV diagnoses (years) |           |                |                |                | 0.667|
| < 5               | 44 (18%)  | 10 (22.7%)     | 11 (15.7%)     | 23 (16.8%)     |    |
| 5–10              | 85 (34%)  | 17 (38.6%)     | 24 (34.3%)     | 44 (32.1%)     |    |
| > 10              | 122 (49%) | 17 (38.6%)     | 35 (50.0%)     | 70 (51.1%)     |    |
| Antiretroviral treatment |           |                |                |                | 0.88 |
| Yes               | 236 (94%) | 42 (95.5%)     | 66 (94.3%)     | 128 (93.4%)    |    |
| No                | 15 (6%)   | 2 (4.5%)       | 4 (5.7%)       | 9 (6.6%)       |    |
| Time with ART (years) |           |                |                |                | 0.471|
| Median (IQR)      | 7.5 (4.8–10.5)| 6.8 (4.2–10.1)| 7.8 (5.2–10.3)| 7.5 (4.6–10.6)|    |
| ART adherence     |           |                |                |                | 0.407|
| All pills         | 222 (94.1%)| 39 (92.9%)     | 60 (90.9%)     | 123 (96.1%)    |    |
| Most of them      | 11 (4.7%) | 3 (7.1%)       | 4 (6.1%)       | 4 (3.1%)       |    |
| Half of them or less |        | 0 (0.0%)       | 2 (3.0%)       | 1 (0.8%)       |    |
| AIDS diagnosis    |           |                |                |                | 0.623|
| Yes               | 52 (20.7%)| 7 (15.9%)      | 14 (20.0%)     | 31 (22.6%)     |    |
| No                | 199 (79.3%)| 37 (84.1%)     | 59 (84.3%)     | 106 (77.4%)    |    |
| CD4 count at last visit (cells/µl) |           |                |                |                | 0.484|
| < 200             | 7 (2.8%)  | 0 (0.0%)       | 1 (1.4%)       | 6 (4.4%)       |    |
| 200–500           | 60 (23.9%)| 11 (25.0%)     | 15 (21.4%)     | 34 (24.8%)     |    |
| > 500             | 184 (73.3%)| 33 (75.0%)     | 54 (77.1%)     | 97 (70.8%)     |    |
| Median (IQR)      | 720 (491–960)| 663 (500–925.5)| 719.5 (527–959)| 731 (476–1016) | 0.929|
| Viral load at last visit |           |                |                |                | 0.279|
| Undetectable(< 200 copies/µl) | 234 (93.2%)| 41 (93.2%)     | 68 (97.1%)     | 125 (91.2%)    |    |
| Detectable(> 200 copies/µl) | 17 (6.8%) | 3 (6.8%)       | 2 (2.9%)       | 12 (8.8%)      |    |
| Women’s health variables |           |                |                |                |    |
| Age at menarche (years) |           |                |                |                | 0.990|
| < 13              | 98 (39%)  | 16 (36.4%)     | 28 (40.0%)     | 54 (39.4%)     |    |
| ≥ 13              | 149 (59%) | 27 (61.4%)     | 41 (58.6%)     | 81 (59.1%)     |    |
| Unknown           | 4 (02%)   | 1 (2.3%)       | 1 (1.4%)       | 2 (1.5%)       |    |
| Number of pregnancies |           |                |                |                |    |
of tobacco, alcohol or drugs, or the prevalence of comorbidities—(hepatitis B, hepatitis C, and diabetes mellitus). However, post-menopausal women were more likely to have osteoporosis than the perimenopausal ones (21.9% vs 10.0%; p < 0.001) and no premenopausal women had osteoporosis.

Regarding the variables related to HIV infection, we did not find significant differences between the three groups. Overall, most of the women (83.7%) had acquired HIV infection through heterosexual practices. Ninety-four percent of the women were receiving antiretroviral therapy (ART), of which 94.1% reported full treatment adherence, 93.2% were virally suppressed, and 73.3% had CD4 count > 500 cells/µl in their last follow-up visit.

Prevalence of menopausal symptoms, severe menopausal symptoms, and anxiety and depression according to menopausal status

Table 2 shows the number and percentage of women experiencing no, mild, moderate or severe somatic, psychological and urogenital symptoms, according to menopausal status.

Results from multivariable analyses showed that post-menopausal women had twice the likelihood of presenting all somatic (OR 2.63; 95% CI 1.44–4.81), psychological and urogenital symptoms (2.54; 1.42–4.85) than pre-menopausal women. Perimenopausal women had a three-fold increase in the

| Menopausal status | All women | Pre-menopausal | Peri-menopausal | Post-menopausal | p value |
|-------------------|-----------|----------------|-----------------|-----------------|---------|
| None              | 251 (100%)| 44 (17.5%)     | 70 (27.9%)      | 137 (54.6%)     | 0.344   |
| 1 or 2            | 114 (45.4%)| 17 (38.6%)     | 27 (38.6%)      | 70 (51.1%)      |         |
| ≥ 3               | 101 (40.2%)| 20 (45.5%)     | 30 (42.9%)      | 51 (37.2%)      |         |

Table 2 Number and percentage of women experiencing no, mild, moderate or severe somatic, psychological and urogenital symptoms according to menopausal status

|               | Pre-menopausal | Peri-menopausal | Post-menopausal | p value |
|---------------|----------------|-----------------|-----------------|---------|
| Somatic symptoms [N (%)] | N = 44 | N = 70 | N = 137 | 0.321 |
| No symptoms   | 29 (65.9%)     | 28 (40.0%)     | 57 (41.6%)     |         |
| Mild          | 8 (18.2%)      | 19 (27.2%)     | 30 (21.9%)     |         |
| Moderate      | 5 (11.4%)      | 16 (22.8%)     | 40 (29.2%)     |         |
| Severe        | 2 (4.5%)       | 7 (10.0%)      | 10 (7.3%)      |         |
| Psychological symptoms [N (%)] | 0.073 |
| No symptoms   | 26 (59.1%)     | 32 (45.7%)     | 54 (39.4%)     |         |
| Mild          | 8 (18.2%)      | 11 (15.7%)     | 24 (17.5%)     |         |
| Moderate      | 4 (9.1%)       | 14 (20.0%)     | 31 (22.6%)     |         |
| Severe        | 6 (13.6%)      | 13 (18.6%)     | 28 (20.4%)     |         |
| Urogenital symptoms [N (%)] | 0.017 |
| No symptoms   | 25 (56.8%)     | 36 (51.4%)     | 51 (37.2%)     |         |
| Mild          | 6 (13.6%)      | 15 (21.4%)     | 24 (17.5%)     |         |
| Moderate      | 10 (22.7%)     | 13 (18.6%)     | 28 (20.4%)     |         |
| Severe        | 3 (6.8%)       | 6 (8.6%)       | 34 (24.8%)     |         |
Table 3  Prevalence of somatic, psychological and urogenital symptoms and of anxiety/depression and OR (95% CI) for its association with menopausal status

|                      | Somatic symptoms | | Psychological symptoms | | Urogenital symptoms | | Anxiety/depression |
|----------------------|------------------|--|-----------------------|--|---------------------|--|-------------------|
|                      | Crude            | Adjusted<sup>a</sup> | Crude      | Adjusted<sup>a</sup> | Crude    | Adjusted<sup>a</sup> | Crude    | Adjusted<sup>a</sup> |
|                      | N (%) OR [95% CI]| OR [95% CI]       | N (%) OR [95% CI] | OR [95% CI]       | N (%) OR [95% CI] | OR [95% CI]       | N (%) OR [95% CI] | OR [95% CI] |
| Pre-menopause (N = 44) |                  |                |            |                     |                     |                     |                     |               |
|                      | 15 (34.1%) 1     | 1              | 18 (40.9%) 1 | 1                    | 19 (43.2%) 1       | 1                    | 5 (11.4%) 1       | 1               |
| Peri-menopause (N = 70) | 42 (60.0%) 2.90 [1.37–6.16] | 3.01 [1.38–6.55] | 38 (54.3%) 1.72 [0.71–4.16] | 2.18 [0.87–5.40] | 34 (48.6%) 1.24 [0.65–2.4] | 1.09 [0.57–2.09] | 13 (18.6%) 1.78 [0.69–4.60] | 2.33 [0.69–7.85] |
| Post-menopause (N = 137) | 80 (58.4%) 2.71 [1.57–4.69] | 2.63 [1.44–4.81] | 83 (60.6%) 2.22 [1.21–4.06] | 2.16 [1.13–4.14] | 86 (62.8%) 2.22 [1.26–3.90] | 2.54 [1.42–4.85] | 30 (21.9%) 2.19 [0.88–5.41] | 1.66 [0.48–5.67] |
| p value              | 0.011            | 0.072          | 0.030                   | 0.300               |                     |                     |                     |               |

Bold values are statistically significant

OR Odds Ratio from logistic regression for the association between menopausal status at the presence of menopausal symptoms in each MRS domain and of anxiety/depression

<sup>a</sup> Adjusted for mode of transmission, current occupational status, smoking, drug use, social support, current partner
likelihood for developing somatic symptoms (OR: 3.01; 95% CI 1.38–6.55) than pre-menopausal women, but no significant differences between pre- and peri-menopausal women were found for psychological or urogenital symptoms. Besides menopausal status and after adjusting for it, other factors that were significantly associated with a higher likelihood of presenting menopausal symptoms were being a current smoker for somatic symptoms (OR 1.90; 95% CI 0.95–3.82), being unemployed as well as having a low social support for psychological symptoms (OR 3.30; 95% CI 1.70–6.42 and OR 4.81; 95% CI 11.86–12.46, respectively) and having a current partner for urogenital symptoms (OR: 2.99; 95% CI 1.82–4.390).

We did not find any significant difference in the prevalence of anxiety and depression according to menopausal status (Table 3).

Prevalence of severe somatic, psychological and urogenital symptoms and OR for their association with menopausal status are shown in Table 4. Results from multivariable analyses showed that post-menopausal women had a statistically significant five-fold increase in the likelihood of presenting severe urogenital symptoms than pre-menopausal women (OR 4.90; 95% CI 1.74–13.84). Other factors that increased the likelihood of presenting severe menopausal symptoms, after adjustment for menopausal status, were the current or past use of drugs for both psychological and urogenital symptoms (OR 2.78; 1.23–6.28 and 3.74; 1.78–7.87, respectively), having a low social support for psychological symptoms (3.22; 1.43–7.26) and being unemployed for somatic symptoms (OR 2.48; 95% CI 1.01–6.12).

The prevalence of each specific symptom in each group is shown in Fig. 1. Overall, the five most commonly reported menopause symptoms were joint/muscle complaints (64%; 95% CI 58–70%), feeling exhausted (58%; 52–64%), sleeping disorders (55%; 49–62%), feeling depressed (47%; 41–53%), and sweating/flush (42%; 36–49%). With the exception of joint and muscle complaints, which were reported more frequently by peri-menopausal women, all the other symptoms were reported more frequently by post-menopausal women, although the differences between the three groups were statistically significant only for sweating and flushes, and vaginal dryness (Fig. 1).

The women were also interviewed about their knowledge and use of selected medications to treat menopausal symptoms. Only 15.9% of pre-, 22.9% of peri- and 27.0% (p = 0.314) of post-menopausal women were aware of hormone replacement therapy (HRT) for menopausal symptoms. The use of HRT was infrequent among these women: four post-menopausal women had received HRT in the past and one pre- and one post-menopausal women were currently using it. These two patients both reported menopausal symptoms in the psychological and urogenital subscales.

Regarding other therapies, 13.6%, 22.9% and 29.9% (p = 0.084) of pre-, peri- and post-menopausal women, respectively, had used non-hormonal lubricants for vaginal dryness. The use of vaginal lubricants was higher among women who experienced moderate or severe urogenital symptoms than among those who had no or mild urogenital symptoms (33.1% versus 15.2%; p = 0.001). Alternative medicines were used to treat menopausal symptoms by 4.6%, 15.7% and 21.9% of pre-, peri- and post-menopausal women, respectively (p = 0.027). Women who had moderate or severe symptoms in the psychological and somatic domains used alternative medicines more frequently than those who

| Table 4 | Prevalence of severe somatic, psychological and urogenital symptoms and OR (95% CI) for its association with menopausal status |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Severe somatic symptoms |                | Severe psychological symptoms |                | Severe urogenital symptoms |                |
|                | Crude | Adjusted* | Crude | Adjusted* | Crude | Adjusted* | Crude | Adjusted* |
|                | N (%) | OR [95% CI] | OR [95% CI] | N (%) | OR [95% CI] | OR [95% CI] | N (%) | OR [95% CI] | OR [95% CI] |
| Pre-menopause (N = 44) | 2 (4.5%) | 1 | 1 | 6 (13.6%) | 1 | 1 | 3 (6.8%) | 1 | 1 |
| Peri-menopause (N = 70) | 7 (10.0%) | 2.33 [0.46–11.82] | 3.79 [0.79–18.24] | 13 (18.6%) | 1.44 [0.54–3.89] | 2.31 [0.79–6.80] | 6 (8.6%) | 1.28 [0.38–5.22] | 1.00 [0.27–3.74] |
| Post-menopause (N = 137) | 10 (7.3%) | 1.65 [0.31–8.82] | 2.35 [0.45–12.86] | 28 (20.4%) | 1.63 [0.54–4.88] | 1.96 [0.47–8.08] | 34 (24.8%) | 4.51 [1.42–14.3] | 4.90 [1.74–13.84] |
| p value | 0.554 | 0.602 | 0.002 |

Bold values are statistically significant
OR: Odds Ratio from logistic regression for the association between menopausal status and the presence of severe menopausal symptoms in each MRS domain
* Adjusted for mode of transmission, current occupational status, smoking, drug use, social support, current partner
had no or mild symptoms in these subscales (23.0% versus 9.8%; \( p = 0.006 \) and 23.4% versus 9.6%; \( p = 0.004 \), respectively).

**Discussion**

In this study we have evaluated the prevalence of somatic, psychological and urogenital symptoms and of anxiety/depression, and its association with menopausal status in women living with HIV from a national cohort. Compared to pre-menopausal women, peri- and post-menopausal women were more likely to experience any somatic symptoms, and post-menopausal women were more likely to experience any psychological and urogenital symptoms. Furthermore, post-menopausal women were more likely to experience severe urogenital symptoms than pre-menopausal women. However, when we evaluated specifically anxiety and depression, we did not find a significant association with menopausal status.

The sample included mostly Spanish women with medium or high educational level, and half of them were currently employed. The vast majority were receiving antiretroviral treatment and had a good clinical and immunological situation. The sociodemographic and clinical variables among pre-, peri- and post-menopausal women were similar.

Being recently diagnosed with HIV is one of the inclusion criteria for the CoRIS cohort, and therefore peri- and post-menopausal women were diagnosed at an older age than premenopausal ones; the three groups had similar times since HIV diagnosis and since ART initiation.

The age at menopause in women living with HIV varies widely among different published studies. Some studies have indicated an earlier onset of menopause among these women compared to HIV-negative ones [9, 24, 25], while others observed a similar age of onset in both groups [26, 27]. In our study, the age of menopause was 48 years, which is similar to that described in the general Spanish population [28].

The clinical profile of women living with HIV infected has a great influence in the onset of menopause, which is influenced by factors such as tobacco and drug use, or low weight. Severe immunodeficiency can affect the length of menstrual cycle and has been associated with early menopause [29]. The proportion of women who used drugs in our cohort was lower than other studies [25], although almost half of women in our study were smokers. The women in our study had a good immunological status, as most of them were receiving ART and the median last CD4 T-cell count was over 700 cells/µl, with 3% having a CD4 T-cell count below 200 cells/µl. Since severe immunodeficiency has been associated with early menopause, starting ART early [30] could improve not only the clinical and immunological situation of women with HIV infection, but it could also lower the risk of an early onset of menopause and its consequences.

It is estimated that 85% of women in Western societies experience menopausal symptoms during years in the menopausal transition. The most common symptoms are hot flushes and night sweats [5, 31], but women can also experience sleep disturbances, fatigue,
irritability, decreased concentration, lack of memory and depression [32]. Women who have had a previous mood disorder are more likely to develop a depression during the menopausal transition [33, 34].

More than half of women analyzed experienced menopausal symptoms. Although around a fifth of them experienced severe urogenital and psychological symptoms, the severity of the somatic symptoms was mild or moderate among most women, as found in other studies [18, 35]. Although several other studies showed that women living with HIV experienced more severe somatic menopausal symptoms than the general population [9, 10], this could be explained because the women included in these studies had multiple vulnerabilities (use of drugs, homelessness, violence and mental health problems) which can increase the severity of menopausal symptoms. In our study, the current or past use of drugs was associated with a higher likelihood of experiencing severe psychological and urogenital symptoms.

Vasomotor symptoms (hot flushes and night sweats) are the most frequent symptoms among women during menopause [5, 36]. Sociodemographic and cultural factors, and ethnicity [37], have been shown to be associated with the prevalence of hot flushes. In our study, 25.0%, 42.9% and 47.4% of pre-, peri- and post-menopausal women, respectively, experienced vasomotor symptoms. Mood disorders have been shown to be associated with vasomotor symptoms [38], and several studies have found an association between hot flushes and depressive symptoms in both HIV-infected and non-HIV infected women [12, 39]. Smoking has also been associated with the presence of hot flushes among HIV-infected [39] and non HIV-infected women [40] and also with depression in HIV-infected individuals [41]. In this study half of peri- and post-menopausal women and 34.1% of pre-menopausal ones were smokers, and smoking was associated with a higher likelihood of presenting somatic symptoms. Social support is an important determinant of mental health and quality of life among HIV-infected women [42]. In our study, women reporting low social support were more likely to experience any and severe psychological symptoms. The prevalence of anxiety and depression did not show statistically significant differences according to menopausal status, but women who self-reported poor social support and who did not have a current partner were significantly more likely to have anxiety/depression compared to those with normal social support or who had a current partner.

Unemployment has been associated with an increased likelihood of depressive symptoms [11, 12]. In our study, being unemployed was associated with a higher prevalence of psychological and severe somatic symptoms, and other employment situation different than being unemployed or having a current employment (such as being retired or being a housewife), was associated with the presence of both somatic and psychological symptoms.

It is worth noting that although post-menopausal women reported psychological symptoms more frequently than pre-menopausal ones as assessed by the MRS, anxiety/depression was not significantly associated with menopausal status when using the PHQ-4 scale. This is probably due to differences in the symptoms that both methods (MRS and PHQ-4) assess, as the MRS includes the symptoms of feeling irritable and exhausted, which were frequent among post-menopausal women.

Menopausal symptoms may undermine ART adherence [18, 43]. In this study, women had good level of adherence and a good immunological status. The percentage of women who took all their pills was high and we did not find differences in the adherence to ART among pre-, peri- and post-menopausal women, nor differences in the adherence according to presence of menopausal symptoms and anxiety/depression (data not shown).

Menopausal symptoms are dependent on several biological, social and cultural factors, and due to the very scarce information in the literature, it is unclear whether women with HIV experience menopause differently. This study adds to the knowledge on menopausal symptoms among women living with HIV, in order to inform clinicians and help them improve care of women with HIV during the menopausal transition. BHIVA guidelines recommend proactive assessment of menopausal symptoms on women aged > 45 years [44]. Given that women with HIV more frequently have insufficient knowledge about menopausal symptoms and what to expect during the menopausal transition [6], it is important that clinicians are aware of these symptoms, how they are expressed among women with HIV and the factors associated with their occurrence in order to give them the necessary information.

The use of HRT was very low among these women, as has been described in other studies among women with HIV infection [27, 45], and also among Spanish women from the general population [28]. So far, European guidelines do not provide specific recommendations about hormonal replacement therapy for menopause [46] and Spanish treatment guidelines for women with HIV infection only recommend it when the benefit outweighs the risk [47]. Conversely, British HIV association guidelines for the sexual and reproductive health of people living with HIV recommend that women living with HIV receive HRT as the HIV-negative population [44]. It is worth nothing that a fifth of the postmenopausal women...
were using alternative medicines to treat menopausal symptoms: this should be taken into account by clinicians as alternative medicine use is frequently not reported by patients and it can cause drug interactions with ART.

Our study has several limitations. We had no data on hormonal levels, such as follicle stimulating hormone (FSH), that would allow a better definition of menopausal status; therefore, the menopausal status was based on self-report about menstrual cycles, as used by other studies [9, 11, 13, 24]. The MRS has been not validated specifically in women living with HIV; however, it has been used in several studies carried out among these women and in different settings. Also, the low number of women in our cohort, reflecting the low proportion of women and in different settings. Also, the low number of women specifically in women living with HIV, however it has been used in several studies carried out among these women and in different settings. Also, the low number of women who were not included in the study had lower education level suggesting a lower socioeconomic status, and were origin- from countries other than Spain and Latin America, which might limit the generalizability of our findings.

In conclusion, in our study women living with HIV aged 45–60 years experienced a wide variety of menopausal symptoms, and some of the symptoms were initiated before women had any menstrual irregularity. We found a high risk of somatic symptoms in peri- and post-menopausal women, and a high risk of psychological and urogenital symptoms in post-menopausal ones. Most somatic symptoms were of low or moderate severity, probably due to the good clinical and immunologi- cal situation of these women. More studies that address needs of women at this stage of life are necessary to iden- tify specific gender gaps.

Abbreviations
HIV: Human immunodeficiency virus; AIDS: Acquired immunodeficiency syn- drome; MRS: Menopause Rating Scale; PHQ-4: Patient Health Questionnaires 4 items; aOR: Adjusted odds ratio; HAART: Highly active antiretroviral therapy; FSH: Follicle stimulating hormone. HRT: Hormone replacement therapy; FSH: Follicle stimulating hormone.

Acknowledgements
This study would not have been possible without the collaboration of all patients, medical and nursery staff and data managers who have taken part in the project. Members of the CoRIS cohort: Executive committee: Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, Maria Isabel González, Federico García, Eva Poveda, Jose Antonio Iribarren, Felix Gutiérrez, Rafael Rubio, Francesc Vidal, Juan Berenguer, Juan González, M Ángeles Muñoz- Fernández. Fieldwork data management and analysis: Immaculada Jarrín, Belén Alegos, Cristina Moreno, Carlos Iniesta, Luis Miguel García Sousa, Nieves Sanz Perez, Marta Rava. BioBank HIV: General Hospital Universitary Gregorio Marañón: M Ángeles Muñoz-Fernández, Irene Consuegra Fernández. Hospital General Universitario de Alicante (Alicante): Esperanza Merino, Gemma Garcia, Irene Portilla, Iván Agea, Joaquín Portilla, Jose Sánchez-Payá, Juan Carlos Rodríguez, Lina Gimeno, Livia Giner, Marcos Diez, Melissa Camarés, Sergio Reus, Vicente Boix, Diego Torrión. Hospital Universitario de Canarias (San Cristóbal de la Laguna): Ana López Liola, Dáil García, Felicitas Diaz-Flores, Juan Luis Gómez, María del Mar Alonso, Ricardo Pelazas, Jehovana Hernández, María Remedios Almán, María Immaculada Hernández. Hospital Universitario Central de Asturias (Oviedo): Víctor Asens, Eulalia Valle, María Eugenia Rivas Carmenato, Tomás Suárez-Zamraca Secades, Laura Pérez. Hospital Universitario 12 de Octubre (Madrid): Rafael Rubio, Federico Pulido, Ortia Bisbal, Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu. Hospital Universitario de Donostia (Donostia-San Sebastián): José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-arrondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Mr Jesús Bustinduy, Kantziak Abértal, Maita Ibarra, Ander Kortabarria and Carmina Oyaga, Mátane Umezur Igartua. Hospital Universitario de Echeg Eache (Elche): Félix Gutiérrez, Mar Masiá, Sergio Padilla, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuari, Rafael Pascual, Marta Fernández, José Alberto García, Xavier Barber, Vanessa Aguullo Re, Javier Garcia Abellán, Reyes Pascual Pérez, María Rocca. Hospital Universitario Germans Trias i Pujol (Can Ruti, Badalona): Roberto Muga, Arantza Sáenz, Daniel Fuster. Hospital General Universitary Gregorio Marañón (Madrid): Juan Berenguer, Juan Carlos López Bernaldo de Quiro, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldaizz-Echevarría, Francisco Tejerina, Francisca José Parras, Pascual Balsalobre, Cristina Diez, Leire Pérez Latorre, Chiara Fanculli. Hospital Universitario de Tarragona Joan XXIII (Tarragona): Francesc Vidal, Joaquín Perar, Consuelo Villadé, Sergio Veloso, Montserrat Vargas, Montserrat Olona, Amigó-Llill, Esther Rodriguez-Gonzalez, Alfonso Baños, Miguel Pérez-Dupla. Hospital Universitario y Politcnic of La Fe (Valencia): Marta Montero Alonso, José López Aldeguer, Marino Blanes Juli, Maria Taisas Pitar, Ivan Castro Hernández, Eva Calabuig Muñoz, Sandra Cuelllar Tovar, Miguel Salavert Llet, Juan Fernández Navarro. Hospital Universitario La Paz (Madrid): José Ramón Blanco, Juan González-García, Francisco Amalith, José Ramón Arribas, José Ignacio Bernardino de la Serna, Carmen Busca, Joanna Cano, Julen Cardinhtianos, Juan Miguel Castro, Ana Delgado Hierro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García-Hortelano, Alania González-Baeza, Rosa of Miguel, Maria Luz Martín-Carbonero, Maria Mayoral, Maria Jose Mellado, Rafael Esteban Mican, Rocío Montejoan, Maria Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Guadalupe Ria Cebrián, Berta Rodr, Talsa Sainz, Elena Sendagorta, Eulalia Valent, Hospital San Pedro, Centro de Investigación Biomédica de La Rioja (CIBIR): Lorenzo, Jose Ramón Moreno, José Antonio Otero, Valvanera Ibarra, Luis Metol, Mercedes Sanz, Laura Pérez-Martínez. Hospital Universitario Miguel Servet (Zaragoza): Piedad Arazo, Gloria Sampén, Hospital Universitario Mutua Terrassa (Terrassa): David Dalmau, Angeles Jaen, Montse Sammart, Mireia Caixo, Javier Martinez-Lacasa, Pablo Velli, Roar Font, Marina Martinez, Francesco Aiello. Complejo Hospitalario de Navarra (Pamplona): Maria Rivero Marcotegia, Jesus Reparaz, Maria Gracia Ruiz de Alda, Maria Teresa de León Cano, Beatriz Pierola Ruiz of Galaretar, Corporación Santar Sanitario Par Caubal (Badalona): Maria José Arangü, Gemma Navarro, Manel Cervantes Garcia, Sonia Calzado Iber, Marta Navarro Vilaros. Hospital Universitario de La Princesa (Madrid). Ignacio of los Santos, Jesus Sanz Sanz, Ana Salas Aparicio, Carmen Sarria Cepeda, Lucía Garcia-Fraile Fraile, Enrique Martinez Gayo. Hospital Universitario Ramón y Cajal (Madrid): Santiago Moreno, Jose Luis Casado Cisner, Fernando Dordona Núñez, Ana Moreno Zamora, Maria Jesús Pérez Elia, Carolina Gutiérrez, Naida Madrid, Santos del Campo Terrón, Sergio Serrano Villar, María Jesús Vivancos Gallego, Javier Martinez Sanz, Usma Anxa Urroz, Tamara Velasco. Hospital General Universitary Reina Sofia (Murcia): Enrique Bernal, Alfredo Cano Sanchez, Antonia Alcaraz Garcia, Joaquin Bravo Urieta, Ángeles Muñoz Perez, Maria Jose Alcaraz, Maria del Carmen Villalba. Hospital Nuevo San Cecilio (Granada): Federico Garcia, José Hernández Quero, Leopoldo Muñoz Medina, Marta Alvarez, Natalia Chueca, David Vinuesa Garcia, Clara Martinez-Montes, Carmen Guerro Beltrán, Adolfo of Salazar González, Ana Fuentes Lopez. Centro Sanitario Sindoal (Madrid): Jorge Del Romero, Montserrat Raposo Utrilla, Carmen Rodriguez, Teresa Puerta, Juan Carlos Carrí, Mar Vera, Juan Ballesteros, Oskar Ayerd. Hospital Clínico Universitary de Santiago (Santiago de Compostela): Antonio Antela, Elena Losada. Hospital Universitario Son Espases (Palma de Mallorca): Melchor Riera, Maria Peñaranda, Mª Ángels Ribes, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas, Francisco Horman, Helen H Vilchez, Maria Luisa Martin, Antonio Payeras. Hospital Universitario Virgen de la Victoria (Malaga): Jesús Santos, Cristina Gómez Ayerbe, Isabel Vicario, Rosario Palacios, Carmen Pérez López, Carmen María González-O孽men, Hospital Universitario Virgen del Rocío (Sevilla): Pompeyo Vicario, Nuria Espona, Luis Fernando López-Cortés. Hospital Universitario de Bellvitge (Hospitaliet de Llobregat): Daniel Podzamczer, Arkaiz Imaz, Juan Tiraboschi, Ana Silva, Maria Saumy,
This work was supported by the Instituto de Salud Carlos III through the Red Funding involved in study design, revised the manuscript for important intellectual statistical analysis. VH, ISG, BA and IJ drafted the manuscript. All authors were in the appendix, were involved in data collection. VH and BA performed the VH, BA and ISG initiated this project. All authors, and CoRIS contributions listed Guillermo Pousada.

Alexandre Pérez, Manuel Crespo, Luis Morano, Celia Miralles, Antonio Ocampo, Alejandro Gonzalez-Serna. Hospital Álvaro Cunqueiro (Vigo): Eva Poveda, Rivero Juárez, Pedro López López, Isabel Machuca Sánchez, Mario Frias Casas, Hernández Gutiérrez, María Novella Mena. Hospital Clínico Universitario de Asturias (Alcalá de Henares): José Sanz Moreno, Alberto Arranz Caso, Cristina Alfonso Cabello, Beatriz Álvarez, Laura Prieto. Hospital Universitario Príncipe de María Jesús Téllez Molina, Jorge Vergas García, Juncal Pérez-Somarriba Moreno. Alberto de Zarraga. Hospital Clínico San Carlos (Madrid): Vicente Estrada Pérez, Balghata, María Amparo Gómez Vidal. Hospital San Agustín (Avilés): Miguel Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, MP Pilar Ruiz Seco. Hospital Universitario de Jaén (Jaén): Mohamed Omar Mohamed-Balg homophobic and with permission of the Spanish AIDS Research Network. Data are available from the corresponding author upon reasonable request (PI15CIII/00027).

Consent for publication

Not applicable.

Competing interests

ISG has received consultation fees from PDI, ViV HealthCare and Gilead. BA has received conference grants from ViV HealthCare. IJ has received teaching fees from ViV HealthCare and fees for advisory boards from Gilead. All other authors declare no competing interests.

Author details

1 Infectious Diseases Group, Department of Internal Medicine, Hospital Universitario Infantia Sofia, FIBB HUJIS HHIEN, Madrid, Spain. 2 Universidad Europea de Madrid, Madrid, Spain. 3 National Center for Epidemiology, Institute of Health Carlos III, Avda. Monforte de Lemos, S, 28029 Madrid, Spain. 4 Hospital Universitario Ramón Y Cajal, IRYCIS, Madrid, Spain. 5 Hospital Universitario de Donostia, ISS BioDonostia, San Sebastian, Spain. 6 Instituto de Investigación Hospital Universitario Doce Octubre, Madrid, Spain. 7 Hospital Universitario Gregorio Marañón, Madrid, Spain. 8 Hospital Universitario La Fe, Valencia, Spain. 9 Institute of Health Carlos III, Telemedicine and E-Health Unit, Madrid, Spain.

Received: 30 November 2020 Accepted: 21 May 2021

Published online: 28 May 2021

References

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (London, England). 2008;372(9635):293–9.

2. Unidad de Vigilancia del VIH y conductas de riesgo. Vigilancia epidemiológica del VIH y sida en España. Sistema de Información sobre Nuevos Diagnósticos de VIH y Registro Nacional de Casos de sida. Madrid: Centro Nacional de Epidemiología-Instituto de Salud Carlos III/Plan Nacional sobre el sida-S.G. de Promoción de la Salud y Vigilancia en Salud Pública; 2019.

3. Encuesta Hospitalaria de pacientes con infección por el VIH. Resultados 2018. Análisis de la evolución 2003–2018. Madrid: Centro Nacional de Epidemiología – Instituto de Salud Carlos III / Plan Nacional sobre el Sida - S.G. de Promoción de la Salud y Vigilancia en Salud Pública; 2019.

4. WHO Technical Report Se No. 866. Geneva: World Health Organization (WHO); 1996.

5. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med. 2005;118(1 Suppl. 1):14–24.

6. Andany N, Kennedy VL, Aden M, Lourtyf M. Perspectives on menopause and women with HIV. Int J Women's Health. 2016;8:1–22.

7. Robertson K, Bayon C, Molina JM, McHarnara P, Resch C, Munoz-Moreno JA, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected women in Western Europe and Canada. AIDS Care. 2014;26(12):1555–61.

8. Miners A, Phillips A, Krefl N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1(11):e32–40.

9. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhães J. Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol. 2007;23(4):198–205.

10. Looby SE, Shiffen J, Corles J, Rope A, Pedersen MC, Joffe H, et al. Increased hot flush severity and related interference in perimenopausal human immunodeficiency virus-infected women. Menopause (New York, NY). 2014;21(4):403–9.

11. Lui-Filho JF, Valadares AL, Gomes Dde C, Armanal E, Pinto-Neto AM, Costa-Paiva L. Menopausal symptoms and associated factors in HIV-positive women. Maturitas. 2013;76(2):172–8.

12. Maki PM, Rubin LH, Cohen M, Golub ET, Greenblatt RM, Young M, et al. Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Menopause (New York, NY). 2012;19(11):1215–23.

13. Miller SA, Santoro N, Lo Y, Howard AA, Arnsten JH, Floris-Moore M, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause (New York, NY). 2005;12(3):348–56.

Authors’ contributions

VH, BA and ISG initiated this project. All authors, and CoRIS contributions listed in the appendix, were involved in data collection. VH and BA performed the statistical analysis. VH, ISG, BA and IJ drafted the manuscript. All authors were involved in study design, revised the manuscript for important intellectual content and contributed to the final version of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0075/0018 and RD16/0002/0006) as part of the Plan Nacional I+D+i and cofinanced by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and Accion Estrategica en Salud Intramural (PI15S12/00027).

Availability of data and materials

Data are available from the corresponding author upon reasonable request and with permission of the Spanish AIDS Research Network.

Declarations

Ethics approval and consent to participate

Ethical approval has been obtained from all hospitals’ Ethics’ Committees and every patients provides written informed consent to participate in the cohort. This project has been approved by Research Ethics Committee of Institute of Health Carlos III (CEI_P1_78_2016). We declare that all methods were carried out in accordance with relevant guidelines and regulation.

Consent for publication

Not applicable.
Sobrino-Vegas P, Gutierrez F, Berenguer J, Labarga P, Garcia F, Alejos-Ferreiras B, et al. The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank: organizational issues, main findings and losses to follow-up. Enferm Infecct Microbiol Clin. 2011;29(9):645–53.

Tariq S, Burns FM, Gilron R, Sabin C. PRIME (Positive Transitions Through the Menopause) Study: a protocol for a mixed-methods study investigating the impact of the menopause on the health and well-being of women living with HIV in England. BMJ Open. 2019;9(6):e025497.

Heinemann K, Ruebig A, Poathoff P, Schneider HP, Strelow F, Heinemann LA, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004;2:45.

Duff PK, Money DM, Ogilvie GS, Ranville F, Kestler M, Braschel MC, et al. Severe menopause symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver. Menopause (New York, NY). 2018;25(5):531–7.

Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–21.

Löwe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122(1–2):86–95.

Gjesfjeld CD, Greeno CG, Kim KH. A confirmatory factor analysis of an abbreviated social support instrument: the MOS-SS. Res Soc Work Pract. 2008;18(3):231–41.

Alejos B, Suárez-García I, Bernardo JI, Blanco JR, Péñaranda M, Bautista A, et al. Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort. Antiviral Ther. 2021;25:335–40.

Solomon D, Sabin CA, Burns F, Gilron R, Allan S, de Ruiter A, et al. The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV. AIDS Care. 2021;33(1):101–8.

Boonyanurak P, Bunupuradah T, Wilawan K, Lueanyod A, Thongpaeng P, Chatvong D, et al. Age at menopause and menopause-related symptoms in human immunodeficiency virus-infected Thai women. Menopause (New York, NY). 2012;19(7):820–4.

Stewart DW, Jones GN, Minor KS. Smoking, depression, and gender in low-income African Americans with HIV/AIDS. Behav Med (Washington, DC). 2011;37(3):77–86.

Soares CN. Mood disorders in midlife women: understanding the critical window and its clinical implications. Menopause (New York, NY). 2014;21(2):198–206.

Sherr L, Molloy A, Macedo A, Cromeone N, Johnson MA. Ageing and menopause considerations for women with HIV in the UK. J Virus Erad. 2016;2(4):215–8.

Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Uitzan W, et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril. 2001;76(5):874–8.

Gold EB, Colvin A, Nisen L, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006;96(7):1226–35.

Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin N Am. 2018;45(4):629–40.

Looby SE, Pisars C, Raggio G, Rivard C, Smeaton L, Shifren J, et al. Association between HIV status and psychological symptoms in perimenopausal women. Menopause (New York, NY). 2018;25(6):648–56.

Gallicchio L, Miller SR, Kiefer J, Greene T, Zacur HA, Flaws JA. Risk factors for hot flashes among women undergoing the menopausal transition: baseline results from the Midlife Women’s Health Study. Menopause (New York, NY). 2015;22(10):1098–107.

Freeman EW. Associations of depression with the transition to menopause. Menopause (New York, NY). 2010;17(4):823–7.

Santoro N, Lo Y, Moskaleva G, Arnsten JH, Floris-Moore M, Howard AA, et al. Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women. Menopause (New York, NY). 2007;14(5):859–65.

Cheung AM, Chaudhry R, Kapral M, Jackevicius C, Robinson G. Perimenopausal and postmenopausal health. BMC Womens Health. 2004;4(Suppl 1):S23.